<DOC>
	<DOCNO>NCT00038649</DOCNO>
	<brief_summary>The goal clinical research study see high dos imatinib mesylate ( Gleevec , STI571 ) improve chronic myelogenous leukemia ( CML ) chronic phase .</brief_summary>
	<brief_title>Therapy Early Chronic Phase CML With Higher-Dose Gleevec , Alpha Interferon , Low-Dose Ara-C</brief_title>
	<detailed_description>Imatinib mesylate new oral medication block protein responsible CML Before treatment start , patient physical exam , blood test , bone marrow study . The bone marrow remove large needle . Women able child screen blood urine test pregnancy . Patients study take 400 mg imatinib twice daily ( morning evening ) . If side effect , dose may lower . If take less 800 mg imatinib , take dose per day divide two dos . Imatinib mesylate take large glass water . Bottles contain tablet give patient every 6 month . Unused supply must return end study . After complete 3 12 month therapy , response imatinib mesylate evaluate . If response good , treatment imatinib mesylate alone continue . Treatment may continue 20 year , long judged best control leukemia . Update : June 2010 Blood test recommend 2 time per year . Your doctor discus often blood test . Bone marrow do doctor think necessary check disease . You must return M. D. Anderson least every year . You may need bone marrow test every visit , blood drawn measure amount disease . If leukemia find 2 year longer blood test call PCR do measure amount disease , doctor may talk stop treatment imatinib . If doctor decide stop therapy , blood test PCR do every 3 6 month . You need return M. D. Anderson blood test do . You may blood take local doctor mail M. D. Anderson . If leukemia find PCR blood test , doctor may recommend restart treatment imatinib . You may decide stay treatment imatinib even PCR blood test show sign leukemia 2 year longer . This investigational study . Imatinib mesylate approve CML . A total 125 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients age 15 year old diagnosis Phpositive Bcrpositive CML early chronic phase CML ( diagnosis &lt; 12 month ) . Except hydroxyurea , patient must receive minimal prior therapy , define less 1 month prior IFNa araC . 2 . ECOG performance 02 3 . Serum bilirubin less 2 mg % , serum creatinine le 2mg % 4 . Women pregnancy potential must practice contraception . Women men must continue birth control duration trial least 3 month last dose study drug . 5 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 6 . The definition CML phase follow : ) early chronic phase : time diagnosis therapy &lt; 12 month , late chronic phase : time diagnosis therapy &gt; 12 month ; b ) blastic phase : presence 30 % blast peripheral blood bone marrow ; c ) accelerate phase CML : presence follow feature : peripheral marrow blast 15 % , peripheral marrow basophils 20 % , thrombocytopenia &lt; 100 x 10 ( 9 ) /L unrelated therapy , document extramedullary blastic disease outside liver spleen due past cause 7 . The definition CML phase follow : clonal evolution define presence additional chromosomal abnormality Ph chromosome part accelerate phase CML . Ph chromosome variant complex Ph chromosome translocation consider indicate disease acceleration . We recently find clonal evolution variable prognostic impact may suppress IFNa therapy . Hence patient eligible accelerated phase sign present , analyzed separately . 8 . Inclusion woman minority : As per NIH policy , woman member minority include protocol refer CML population . Their distribution similar general referral profile CML : 50 % CML patient females 25 % 30 % member minority . There exclusion woman minority base study objective . 1 . NYHA class 34 heart disease 2 . Psychiatric disability ( psychosis ) 3 . Pregnant lactating female 4 . Patients late chronic phase , accelerate phase blastic phase exclude .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Philadelphia chromosome positive</keyword>
	<keyword>early chronic phase ( diagnosis &lt; 12 month )</keyword>
	<keyword>Chronic Myelogenous Leukemia , Chronic Phase</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Gleevec</keyword>
	<keyword>STI571</keyword>
</DOC>